Barinthus Biotherapeutics (BRNS) Competitors $0.98 +0.03 (+3.07%) Closing price 01:46 PM EasternExtended Trading$0.98 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. IKT, TIL, ALEC, BDTX, GALT, NLTX, LXEO, LYEL, FTLF, and ALTSShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Inhibikase Therapeutics (IKT), Instil Bio (TIL), Alector (ALEC), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Neoleukin Therapeutics (NLTX), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), FitLife Brands (FTLF), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors Inhibikase Therapeutics Instil Bio Alector Black Diamond Therapeutics Galectin Therapeutics Neoleukin Therapeutics Lexeo Therapeutics Lyell Immunopharma FitLife Brands ALT5 Sigma Inhibikase Therapeutics (NYSE:IKT) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk. Do analysts rate IKT or BRNS? Inhibikase Therapeutics presently has a consensus price target of $6.50, indicating a potential upside of 243.92%. Barinthus Biotherapeutics has a consensus price target of $6.25, indicating a potential upside of 541.03%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, IKT or BRNS? Inhibikase Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.8, meaning that its stock price is 180% less volatile than the S&P 500. Is IKT or BRNS more profitable? Barinthus Biotherapeutics' return on equity of -46.43% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Barinthus Biotherapeutics N/A -46.43%-38.50% Which has higher earnings and valuation, IKT or BRNS? Inhibikase Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.71Barinthus Biotherapeutics$14.97M2.63-$61.07M-$1.64-0.59 Does the media prefer IKT or BRNS? In the previous week, Inhibikase Therapeutics had 3 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Inhibikase Therapeutics and 0 mentions for Barinthus Biotherapeutics. Inhibikase Therapeutics' average media sentiment score of 0.40 beat Barinthus Biotherapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Inhibikase Therapeutics Neutral Barinthus Biotherapeutics Neutral Do insiders and institutionals have more ownership in IKT or BRNS? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 10.7% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryBarinthus Biotherapeutics beats Inhibikase Therapeutics on 10 of the 14 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.33M$2.89B$5.49B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E Ratio-0.5921.5727.4320.06Price / Sales2.63279.49397.78108.02Price / CashN/A41.4736.1356.90Price / Book0.307.518.085.67Net Income-$61.07M-$55.05M$3.16B$248.47M7 Day Performance5.75%3.16%2.13%2.90%1 Month Performance-9.72%5.92%4.44%5.75%1 Year Performance-31.82%5.83%35.63%21.36% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics3.5337 of 5 stars$0.98+3.1%$6.25+541.0%-34.0%$39.33M$14.97M-0.59107Gap UpIKTInhibikase Therapeutics1.3678 of 5 stars$1.95flat$6.50+233.3%+52.9%$144.97M$260K-0.736News CoverageTILInstil Bio2.7453 of 5 stars$21.93+5.3%$119.00+442.6%+137.2%$143.86MN/A-1.83410News CoverageALECAlector3.6596 of 5 stars$1.42+1.4%$4.00+181.7%-65.4%$141.99M$100.56M-1.13270BDTXBlack Diamond Therapeutics3.3091 of 5 stars$2.48flat$12.80+416.1%-38.2%$141.01MN/A41.3390Positive NewsAnalyst UpgradeGALTGalectin Therapeutics1.8362 of 5 stars$2.22+5.2%$6.00+170.3%-4.8%$140.50MN/A-3.089NLTXNeoleukin TherapeuticsN/A$14.95-7.5%N/A-50.1%$140.50MN/A-4.8190High Trading VolumeLXEOLexeo Therapeutics2.5162 of 5 stars$4.22+5.0%$16.60+293.4%-68.8%$140.09MN/A-1.2858News CoverageLYELLyell Immunopharma2.7402 of 5 stars$9.43+6.7%$15.00+59.1%-68.8%$139.66M$60K-0.38270FTLFFitLife Brands4.0739 of 5 stars$14.14+8.6%$20.50+45.0%-19.0%$132.78M$64.47M16.8320ALTSALT5 Sigma0.1231 of 5 stars$7.57+4.6%N/AN/A$132.10M$12.53M0.00170High Trading Volume Related Companies and Tools Related Companies IKT Competitors TIL Competitors ALEC Competitors BDTX Competitors GALT Competitors NLTX Competitors LXEO Competitors LYEL Competitors FTLF Competitors ALTS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
